A detailed history of Goldman Sachs Group Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 263,607 shares of NUVL stock, worth $24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
263,607
Previous 285,383 7.63%
Holding current value
$24 Million
Previous $21.6 Million 24.56%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$67.44 - $112.17 $1.47 Million - $2.44 Million
-21,776 Reduced 7.63%
263,607 $27 Million
Q2 2024

Aug 13, 2024

BUY
$62.76 - $81.61 $6.72 Million - $8.73 Million
107,014 Added 60.0%
285,383 $21.6 Million
Q1 2024

May 15, 2024

SELL
$72.35 - $88.99 $2.91 Million - $3.58 Million
-40,260 Reduced 18.41%
178,369 $13.4 Million
Q4 2023

Feb 13, 2024

BUY
$42.42 - $80.28 $5.88 Million - $11.1 Million
138,524 Added 172.93%
218,629 $16.1 Million
Q3 2023

May 14, 2024

SELL
$39.12 - $49.85 $5.42 Million - $6.91 Million
-138,524 Reduced 63.36%
80,105 $3.68 Million
Q3 2023

Nov 14, 2023

SELL
$39.12 - $49.85 $301,849 - $384,642
-7,716 Reduced 8.79%
80,105 $3.68 Million
Q2 2023

May 14, 2024

BUY
$23.58 - $44.68 $304,441 - $576,863
12,911 Added 17.24%
87,821 $3.7 Million
Q2 2023

Aug 14, 2023

BUY
$23.58 - $44.68 $304,441 - $576,863
12,911 Added 17.24%
87,821 $3.7 Million
Q1 2023

May 14, 2024

SELL
$25.42 - $33.52 $1.52 Million - $2.01 Million
-59,934 Reduced 44.45%
74,910 $1.95 Million
Q1 2023

May 11, 2023

SELL
$25.42 - $33.52 $1.52 Million - $2.01 Million
-59,934 Reduced 44.45%
74,910 $1.95 Million
Q4 2022

May 14, 2024

BUY
$18.46 - $36.37 $1.88 Million - $3.7 Million
101,647 Added 306.19%
134,844 $4.02 Million
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $1.88 Million - $3.7 Million
101,647 Added 306.19%
134,844 $4.02 Million
Q3 2022

May 14, 2024

SELL
$13.55 - $19.92 $101,015 - $148,503
-7,455 Reduced 18.34%
33,197 $645,000
Q3 2022

Nov 10, 2022

SELL
$13.55 - $19.92 $101,015 - $148,503
-7,455 Reduced 18.34%
33,197 $645,000
Q2 2022

May 14, 2024

SELL
$7.4 - $15.07 $1.32 Million - $2.68 Million
-177,977 Reduced 81.41%
40,652 $552,000
Q2 2022

Aug 15, 2022

BUY
$7.4 - $15.07 $176,157 - $358,741
23,805 Added 141.3%
40,652 $552,000
Q1 2022

May 16, 2022

BUY
$11.65 - $19.57 $25,012 - $42,016
2,147 Added 14.61%
16,847 $234,000
Q4 2021

Feb 14, 2022

BUY
$18.01 - $30.1 $264,747 - $442,470
14,700 New
14,700 $280,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.92B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.